Stoke Therapeutics, INC 8-K filings

Stoke Therapeutics has filed a prospectus supplement to offer up to $200 million in common stock through an at-the-market offering.

Stoke Therapeutics reported Q2 2026 financial results, detailing advancements in its Phase 3 EMPEROR study for zorevunersen in Dravet syndrome and its Phase 1 OSPREY study for STK-002 in ADOA, supported by a robust cash runway.

Stoke Therapeutics announced the completion of enrollment for its Phase 3 EMPEROR study of zorevunersen, a potential treatment for Dravet syndrome, with a data readout anticipated in Q3 2027.

Stoke Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of three Class I directors and the ratification of its independent auditor.

Stoke Therapeutics reported Q1 2026 financial results, highlighting positive 4-year data for zorevunersen in Dravet syndrome and providing updates on Phase 3 enrollment.

Stoke Therapeutics announced the appointment of Dr. Clare Kahn to its Board of Directors, bringing extensive experience in drug development and regulatory strategy.

Stoke Therapeutics' Board of Directors approved a $697,125 discretionary bonus for CEO Ian F. Smith, reflecting strong clinical and financial performance.

Stoke Therapeutics, Inc. has secured a new, larger lease for its corporate headquarters and laboratory in Waltham, Massachusetts, signaling growth.

Stoke Therapeutics announced accelerated timelines for its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with enrollment completion expected in Q2 2026 and data readout in mid-2027, alongside a strong cash position.

Stoke Therapeutics and Biogen presented new data at the AES Annual Meeting, further supporting zorevunersen's potential as a disease-modifying medicine for Dravet syndrome with durable seizure reductions and cognitive improvements.

Stoke Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical programs, including significant progress in the Phase 3 EMPEROR study for Dravet syndrome.

Stoke Therapeutics, Inc. has officially appointed Ian F. Smith as its permanent Chief Executive Officer, effective October 6, 2025, following his tenure as Interim CEO.

Stoke Therapeutics, Inc. announced its decision to hold annual non-binding advisory votes on executive compensation, aligning with stockholder preference and board recommendation.

Stoke Therapeutics reports strong Q2 2025 financial results, initiates Phase 3 for zorevunersen in Dravet syndrome, and advances STK-002 for ADOA.

Stoke Therapeutics and Biogen announced the dosing of the first patient in the global Phase 3 EMPEROR study for zorevunersen, a potential disease-modifying treatment for Dravet syndrome.

Stoke Therapeutics and Biogen presented new data on zorevunersen, an investigational medicine for Dravet syndrome, showing improvements in cognition and behavior at Week 68, which informed the design of the ongoing Phase 3 EMPEROR study.

Stoke Therapeutics, Inc. announced that all proposals, including the re-election of three Class III directors and the ratification of KPMG LLP as its independent auditor, were adopted at its 2025 Annual Meeting of Stockholders.

Stoke Therapeutics has announced the initiation of its Phase 3 EMPEROR study for zorevunersen, a potential disease-modifying therapy for Dravet syndrome, with the first U.S. sites activated in May 2025.

Stoke Therapeutics announces positive Q1 2025 financial results, highlighted by a strategic collaboration with Biogen and progress in the Phase 3 development of zorevunersen for Dravet syndrome.

Stoke Therapeutics reports its full year 2024 financial results, announces the transition of CEO Edward Kaye to an advisory role, and appoints Ian F. Smith as Interim CEO.

Stoke Therapeutics and Biogen have entered into a licensing and collaboration agreement to develop and commercialize zorevunersen for Dravet syndrome, with Biogen gaining exclusive rights outside of the United States, Canada, and Mexico.

Stoke Therapeutics has aligned with global regulatory agencies to initiate a Phase 3 study of zorevunersen, a potential disease-modifying medicine for Dravet syndrome.

Stoke Therapeutics announced it has received Breakthrough Therapy Designation from the FDA for zorevunersen and released positive data from its clinical trials showing substantial reductions in seizure frequency and improvements in cognition and behavior for patients with Dravet syndrome.

Stoke Therapeutics reported its third quarter 2024 financial results, provided updates on its zorevunersen program, and announced plans to share new data by year-end.

Stoke Therapeutics has reached a settlement in a stockholder derivative lawsuit, agreeing to implement changes to its director compensation policies and pay legal fees.

Stoke Therapeutics reported its second quarter 2024 financial results, highlighted by the FDA removing a partial clinical hold on their Dravet syndrome treatment, zorevunersen, and progress towards a Phase 3 study.

Stoke Therapeutics' Chief Operating Officer, Huw Nash, Ph.D., has stepped down from his role, effective immediately, but will continue as Chief Business Officer.

Stoke Therapeutics held its 2024 Annual Meeting of Stockholders on June 5, 2024, where three Class II directors were elected and the appointment of KPMG LLP as the company's independent auditor was ratified.

Stoke Therapeutics announced its first quarter 2024 financial results, highlighted by positive clinical data for STK-001 in Dravet syndrome and a strengthened cash position following a public offering.

Stoke Therapeutics has appointed Thomas Leggett as its new Chief Financial Officer, effective May 7, 2024, replacing Stephen Tulipano who will transition to an advisory role.